Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy

International Clinical Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 125-133

  Nelson, James Craig ^a   Thase, Michael E ^b   Bellocchio, Elizabeth E ^c   Rollin, Linda M ^c   Eudicone, James M ^c   McQuade, Robert D ^d   Marcus, Ronald N ^c   Berman, Robert M ^c   Baker, Ross A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

antidepressant therapy; aripiprazole; major depressive disorder; minimal responder; partial responder

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE;

ADULT; AGED; AKATHISIA; ARTICLE; BLURRED VISION; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INSOMNIA; KAPLAN MEIER METHOD; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESTLESSNESS; SOMNOLENCE; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859245528     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283502791     Document Type: Article

References (26)

1. APA (2010). Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry 167:A34.
2. Berman R, Fava M, Thase M, Swanink R, McQuade R, Carson W, et al. (2009). Aripiprazole augmentation in major depression: a double-blind, placebocontrolled study in patients with inadequate response to antidepressants. CNS Spectr 14:197-206.
3. Berman R, Thase M, Trivedi MH, Hazel J, Marler S, McQuade R, et al. (2011). Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 7:303-312.
4. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychiatry 68:843-853. (Pubitemid 47015482)
5. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389. (Pubitemid 34680462)
6. Citrome L (2011). Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it. J Clin Psychiatry 72:412-413.
7. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364-372. (Pubitemid 44619788)
8. Fava M (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649-659. (Pubitemid 39658481)
9. Fava M, Davidson K (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
10. Fava M,Wisniewski SR, Thase ME, Baker RA, Tran Q-V, Pikalov A, et al. (2009). Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol 29:362-367.
11. Greden JF (2001). The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry 62 (Suppl 22):5-9. (Pubitemid 32937579)
12. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 441:137-140. (Pubitemid 34626163)
13. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA (2004). In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483:45-53. (Pubitemid 38056603)
14. Lakoski JM, Aghajanian GK (1985). Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 24:265-273. (Pubitemid 15149199)
15. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. (2008). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156-165. (Pubitemid 351417120)
16. Mö ller HJ (2008). Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451-455.
17. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
18. Nelson JC (2007). Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies. CNS Spectr 12:6-9.
19. Nelson JC, Papakostas GI (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980-991.
20. Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Tran QV, et al. (2009). Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 11:344-352.
21. Nutt DJ, Davidson JR, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioglu O, et al. (2010). International consensus statement on major depressive disorder. J Clin Psychiatry 71 (Suppl E1):e08.
22. Osby U, Brandt L, Correia N, Ekbom A, Sparen P (2001). Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58:844-850. (Pubitemid 32979302)
23. Robinson D, Alms D, Shrotriya R, Messina M, Wickramaratne P (1989). Serotonergic anxiolytics and treatment of depression. Psychopathology 22:27-32.
24. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 28:1400-1411. (Pubitemid 41070874)
25. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, et al. (2005). Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66:1289-1297. (Pubitemid 41546509)
26. Tadori Y, Forbes RA, Mcquade RD, Kikuchi T (2008). Characterization of aripiprazole partial agonist activity at human dopamine d(3) receptors. Eur J Pharmacol 597:27-33.